Skip to main content
GENB logo

GENB · Generate Biomedicines, Inc.

Track GENB — free
$9.54 -0.83 (-8.00%) At close · Nov 20
Market Cap
$1.23B
Shares
129.10M
Volume · Nov 20 967.86K Avg daily vol (3M) 1.23M

Price & Indicators

 

Key stats

Close
$9.54
Fri 20 Nov
Open
$10.06
Fri 20 Nov
Average volume, 30 days
973K
shares a session
Short interest
9.1M
7.0% of shares · 8.9 days to cover
Day range
$9.40$10.58
Open $10.06 Close $9.54
Available closing range
$9.54$20.38
Close $9.54 53.2% under the high
Short volume, last session
68%
Last earnings
Nov 12, 2026
Latest filing
10-Q · Nov 12
Price history
Feb 2026 to Nov 2026

The closing range uses available history since Feb 27, 2026; less than a full year is stored.

Up next

Feb 15, 2027 Est · unconfirmed · in 12 wks

Latest documents

2026
Nov 16
Investor event
GB0895 asthma phase three trial enrolling across 400 different sites

Generate Biomedicines' lead asthma candidate GB0895, an anti-TSLP molecule, entered phase three trials in December of last year and is enrolling across 400 different sites.

3 source passages
The pipeline starts with GB0895. This is an anti-TSLP molecule. We moved it into phase three trials in asthma in December of last year. We're enrolling across 400 different sites, and the early progress is suggestive that we'll continue to complete the trial by the end of next year. Open the document at this passage
Nov 12
Current report 8-K
Cash runway extends into first half of 2028

Generate Biomedicines reported a $87.7 million net loss and $404.2 million in cash, cash equivalents, and marketable securities as of Sept. 30, 2026; it believes resources including $30.0 million from Zealand will fund its current operating plan into the first half of 2028.

Financial results
4 source passages
Generate Biomedicines, Inc. (Nasdaq: GENB) (“Generate”) today reported financial results for the third quarter ended Sept. 30, 2026, and provided an update on recent business progress. Cash, cash equivalents, and marketable securities were $404.2 million as of Sept. 30, 2026, compared with $457.4 million as of June 30, 2026. Net loss was $87.7 million for the quarter ended Sept. 30, 2026, compared with $60.0 million for the same period in 2025. Generate believes its existing cash, cash equivalents, and marketable securities, together with the $30.0 million upfront payment received from Zealand in October 2026 in connection with the Zealand collaboration, will be sufficient to fund its current operating plan into the first half of 2028. Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Nine-month net loss widens to $216.6 million

Generate Biomedicines reported a $216.6 million net loss and $204.4 million in research and development expenses for the nine months ended September 30, 2026; cash, cash equivalents and marketable securities totaled $404.2 million as of September 30, 2026.

Revenue $4.22M ▼ 56.2% Net loss $87.66M Diluted EPS -$0.68
Read from the MD&A section
4 source passages
Our net losses were $216.6 million and $161.1 million, of which $0.3 million and $13.4 million were attributable to a non-controlling interest for the nine months ended September 30, 2026 and 2025, respectively. Research and development expenses increased to $204.4 million for the nine months ended September 30, 2026 compared to $168.7 million for the nine months ended September 30, 2025. As of September 30, 2026, we had cash, cash equivalents and marketable securities of $404.2 million. Net loss attributable to Generate Biomedicines, Inc. stockholders (216,358) (147,729) (68,629) Open the document at this passage
Nov 9
Investor event
Solaria reaches phase three with suggested six months dosing

Generate Biomedicines said Solaria entered phase three for severe asthma; early data suggested dosing every six months and key biomarker reductions at least as well as tezapelumab.

4 source passages
I'm thrilled to have Generate Biomedicines with us here today, CEO Mike Nally, President and CFO Jason Silvers, to my left sequentially. So can you just help us understand what brought you to phase three so quickly with the Solaria program? You know, our first asset, our lead asset's now in phase three of development. It's going after severe asthma. You know, the early data is suggestive that it will be dosed every six months. It reduces, you know, key biomarkers at least as well, if not better, than what we saw with tezapelumab. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
-56.2%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$404.21M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+289.0%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
7.0%
Latest settlement · 8.9 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.62
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 50-day avg −31%
below
RSI (14) 33
neutral
MACD trend Negative
52-week position 0%
near low
Momentum
relative strength
Very Weak
1-month return −23%
trailing
6-month return −20%
trailing
Relative strength −11%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+27% holders QoQ · +35 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
7.04% of shares out · ▲ +1.7% MoM · 8.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
109 holders — 13F breadth
Squeeze score 64
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 89%
annualized · 1-yr
Max drawdown −53%
past year
ATR 11.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
3 · 2 · 0
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
−31% Bearish
RSI (14)
33 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+27% holders QoQ · +35 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
7.04% of shares out · ▲ +1.7% MoM · 8.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
109 holders — 13F breadth
Price context
position in its available closing range
Range low $10 Now $10 · 0% Range high $20
vs 50-day avg -31%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
CAR signaling domain 70% early preclinical research —
Cash, cash equivalents, and marketable securities $457.4M As of June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
GENB
Generate Biomedicines, Inc.
this stock
$1.23B — — — 7.0%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
109
% held
82.7%
Net QoQ
+6.7M sh
Top holder
Flagship Pioneering, LLC
Held Float
View
Held by Funds
Fund positions
109
View
Short & Settlement
Short Interest Rising
Shares short
9.1M
Days to cover
8.9d
Change
+154.1K sh
View
Short Volume
Short vol %
68%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
25.1K
Value
$396.1K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
45.5%
Week of
Oct 12, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 16, 2026
This year
16

Generate Biomedicines' lead asthma candidate GB0895, an anti-TSLP molecule, entered phase three trials in December of last year and is enrolling across 400 different sites.

View
Proposed Sales
Value
$184.7K
Shares
11.4K
Filed
Oct 29, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 16, 2026
View
Investor Relations
Latest news
Generate Biomedicines Reports Thi…
Published
Nov 12, 2026
View

Performance

5D 20D 120D MTD YTD
GENB -21.0% -23.1% -20.3% -34.0% —
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -12.4% -13.9% -11.1% -25.3% —
Key facts CIK 2100782 CUSIP 370920100 13F (30d) 100 filings 98 filers Visit website Investor relations